Minimal Residual Disease Evaluation on Cryopreserved Ovarian Fragments in Younger Patients Treated for Acute Myeloid Leukemia

University Hospital, Lille9 enrolled

Overview

Cryopreservation of ovarian cortex represents an option for fertility preservation in patients diagnosed with acute myeloid leukemia and requiring allogeneic stem cell transplantation. This pilot study aims to evaluate the minimal residual disease on ovarian fragments harvested before allogeneic stem cell transplantation at the time of complete remission.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Acute Myeloid Leukemia

Eligibility

Sex: FEMALEMin age: 2 YearsMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient diagnosed with AML * At least one molecular marker identified at AML diagnosis * Patients who undergo ovarian tissue cryopreservation for fertility preservation in complete remission, before hematopoietic stem cell transplantation. Exclusion Criteria: * Other diagnostic * No marker available at AML diagnosis * No bone marrow/ovarian fragment available at the time of complete remission

Locations (1)

CHU lille

Lille, France

Outcomes

Primary Outcomes

Percentage of patients without detectable MRD in ovarian tissue

Time frame: Up to 6 months

Secondary Outcomes

Percentage of patients with MRD detected in ovarian tissue and bone marrow.

Time frame: Up to 1 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.